Cagrilintide side effects: a gastrointestinal, titration-shaped profile

Cagrilintide is a long-acting amylin analog being studied for weight management, both on its own and as the amylin half of the fixed-dose combination CagriSema. Because amylin slows gastric emptying and acts on appetite circuits, its tolerability story looks a lot like the incretin-drug class — the side effects are mostly in the gut, mostly dose-related, and mostly transient. For the efficacy context behind these trials, see the CagriSema REDEFINE evidence read.

The headline: gastrointestinal effects

The most common adverse events with cagrilintide are gastrointestinal. In the dose-finding Phase 2 monotherapy trial in people with overweight or obesity, the predominant adverse events were gastrointestinal in nature and rose with dose.^[1] Across the CagriSema program, the tolerability profile carried the same signature: gastrointestinal events — nausea, vomiting, constipation, and diarrhea — were the most frequently reported class of side effect in the REDEFINE 1 obesity trial.^[2] This is a direct, expected consequence of how the drug works: amylin agonism slows gastric emptying, so food sits longer and the gut registers it differently, which is the same mechanism that produces the appetite effect the drug is prescribed for.

Why the gut bears the brunt

Amylin is co-secreted with insulin and one of its physiological jobs is to put a brake on how fast the stomach empties and to signal satiety. A long-acting analog like cagrilintide amplifies that braking. The upside is reduced appetite and earlier fullness; the downside is that the same delayed emptying can present as nausea, occasional vomiting, and altered bowel habit. In the Phase 1b combination study that paired cagrilintide with semaglutide, the co-administration was judged tolerable with a safety profile consistent with each component — with gastrointestinal events again the dominant theme.^[3]The effects are real, but they are mechanistic and predictable rather than idiosyncratic.

Dose- and titration-related — and usually transient

A consistent feature is that the gastrointestinal effects track the dose. They are most prominent when the dose is being escalated and tend to subside as treatment continues, which is why these drugs are introduced on a gradual titration schedule rather than at the full dose.^[1]The practical implication is that a slower dose-up tends to be better tolerated, and that early nausea is not necessarily a reason to stop — though it is a reason to titrate carefully and stay in contact with a prescriber.

Injection-site and appetite-driven effects

Beyond the gut, cagrilintide is a weekly subcutaneous injection, so injection-site reactionsare part of the profile, as with other injectable peptides.^[2] The other category worth naming is the appetite-suppression effects themselves: markedly reduced food intake and early satiety are the intended pharmacology, but at the individual level they can shade into reduced enjoyment of food or unintentionally low intake if not managed. These are the flip side of the mechanism that drives weight loss, not separate toxicities.

How it compares: GLP-1 alone vs the combination

Because cagrilintide and the GLP-1 agonist semaglutide both lean on the gut and appetite, their side-effect profiles rhyme. In the REDEFINE program, the combination’s tolerability was broadly the gastrointestinal-class profile seen with GLP-1 therapy — the same kinds of events, and again dose-dependent.^[2] Stacking two appetite pathways does not introduce a wholly new category of adverse effect; the meaningful question is whether combining them intensifies the familiar gastrointestinal load, which is exactly the kind of trade-off the Phase 3 dataset was built to characterize. The REDEFINE 2 trial extended this to adults who also had type 2 diabetes and reported a comparable, manageable safety picture in that group.^[4] A secondary REDEFINE 1 analysis also noted reductions in blood pressure with the combination, a cardiometabolic effect rather than an adverse one.^[5]

The honest bottom line

Cagrilintide’s side effects are, overwhelmingly, gastrointestinal: nausea, vomiting, constipation, and diarrhea, driven by amylin slowing the stomach, and largely transient as the dose is titrated up.^[1]Add injection-site reactions and the appetite effects that are inseparable from how the drug works, and that is most of the picture — a profile that closely mirrors the GLP-1 class it is often paired with.^[2] What it does not yet have is the long horizon of real-world safety data; as an investigational compound, the prudent reading is that the known effects are manageable and predictable, but the long-term verdict is not in.